Compare Cipla with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs LUPIN - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA LUPIN CIPLA/
LUPIN
 
P/E (TTM) x 27.0 -64.0 - View Chart
P/BV x 3.8 3.0 126.9% View Chart
Dividend Yield % 0.6 0.7 80.2%  

Financials

 CIPLA   LUPIN
EQUITY SHARE DATA
    CIPLA
Mar-21
LUPIN
Mar-21
CIPLA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs8791,122 78.3%   
Low Rs411576 71.3%   
Sales per share (Unadj.) Rs237.6334.2 71.1%  
Earnings per share (Unadj.) Rs29.827.0 110.1%  
Cash flow per share (Unadj.) Rs43.046.6 92.3%  
Dividends per share (Unadj.) Rs5.006.50 76.9%  
Avg Dividend yield %0.80.8 101.3%  
Book value per share (Unadj.) Rs226.7300.1 75.6%  
Shares outstanding (eoy) m806.46453.68 177.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x2.72.5 106.8%   
Avg P/E ratio x21.631.4 69.0%  
P/CF ratio (eoy) x15.018.2 82.3%  
Price / Book Value ratio x2.82.8 100.5%  
Dividend payout %16.824.0 69.8%   
Avg Mkt Cap Rs m519,826385,072 135.0%   
No. of employees `000NANA-   
Total wages/salary Rs m32,51828,259 115.1%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m191,596151,630 126.4%  
Other income Rs m2,6981,363 197.9%   
Total revenues Rs m194,294152,993 127.0%   
Gross profit Rs m42,48725,669 165.5%  
Depreciation Rs m10,6778,874 120.3%   
Interest Rs m1,6071,406 114.3%   
Profit before tax Rs m32,90116,751 196.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,8884,485 198.2%   
Profit after tax Rs m24,01312,266 195.8%  
Gross profit margin %22.216.9 131.0%  
Effective tax rate %27.026.8 100.9%   
Net profit margin %12.58.1 154.9%  
BALANCE SHEET DATA
Current assets Rs m132,095139,864 94.4%   
Current liabilities Rs m45,91684,361 54.4%   
Net working cap to sales %45.036.6 122.9%  
Current ratio x2.91.7 173.5%  
Inventory Days Days6869 97.8%  
Debtors Days Days7108 6.1%  
Net fixed assets Rs m116,27794,439 123.1%   
Share capital Rs m1,613907 177.7%   
"Free" reserves Rs m181,232135,229 134.0%   
Net worth Rs m182,844136,136 134.3%   
Long term debt Rs m12,028161 7,461.2%   
Total assets Rs m248,372234,302 106.0%  
Interest coverage x21.512.9 166.3%   
Debt to equity ratio x0.10 5,555.2%  
Sales to assets ratio x0.80.6 119.2%   
Return on assets %10.35.8 176.8%  
Return on equity %13.19.0 145.8%  
Return on capital %17.713.3 132.9%  
Exports to sales %31.30-   
Imports to sales %10.90-   
Exports (fob) Rs m59,951NA-   
Imports (cif) Rs m20,911NA-   
Fx inflow Rs m68,05151,027 133.4%   
Fx outflow Rs m20,91121,081 99.2%   
Net fx Rs m47,14029,946 157.4%   
CASH FLOW
From Operations Rs m37,55218,218 206.1%  
From Investments Rs m-23,872-12,396 192.6%  
From Financial Activity Rs m-13,299-18,853 70.5%  
Net Cashflow Rs m509-13,031 -3.9%  

Share Holding

Indian Promoters % 14.3 46.5 30.8%  
Foreign collaborators % 21.8 0.3 7,782.1%  
Indian inst/Mut Fund % 45.9 40.4 113.6%  
FIIs % 24.4 15.3 159.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 63.9 53.2 120.1%  
Shareholders   451,365 361,862 124.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    AUROBINDO PHARMA    DR. REDDYS LAB    CADILA HEALTHCARE    PIRAMAL ENTERPRISES    



Today's Market

Sensex Sheds 427 Points, Nifty Ends Near 17,600; Bajaj Finserv, Tata Steel & Tech Mahindra Top Losers(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended on a weak note.

Related Views on News

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

CIPLA 2020-21 Annual Report Analysis (Annual Result Update)

Oct 20, 2021 | Updated on Oct 20, 2021

Here's an analysis of the annual report of CIPLA for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

Lupin Gains 16% in a Month. Here's Why it Could Rally More (Views On News)

Jun 4, 2021

Recent developments in digital healthcare and revised targets by brokerages send Lupin shares flying.

What's Behind the Rally in Pharma Stocks? (Views On News)

May 11, 2021

The second wave of Covid has given a new lease of life to pharma stocks.

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

More Views on News

Most Popular

10 Indian Companies with the Fastest Growth in Dividend Payouts...(Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better?(Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain(Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive?(Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

Time to Buy Energy Stocks(Fast Profits Daily)

Jan 14, 2022

Energy is a sector that looks set to take off. It's time to get in.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jan 21, 2022 (Close)

TRACK CIPLA

CIPLA - SYNCOM FORMULATIONS COMPARISON

COMPARE CIPLA WITH

MARKET STATS